In clinical trials, monotherapy with extended-release calcifediol in patients with stage 3 or 4 CKD achieves dose-dependent increases of 25(OH)D and physiological increases in 1,25(OH)2D, accompanied by sustained reduction of parathyroid hormone and little or no impact on mineral balance or FGF23 levels. Here, PTH is linked to chronic kidney disease.